Entropy NeurodynamicsTYPTF -45.63% 3-Year ROIIC % is -147.87 as of Jun. 2025. The stock has 5 warning signs investors should review. Among 1,323 Biotechnology companies, Entropy Neurodynamics ranks worse than 76.57% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Entropy Neurodynamics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was -147.87%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Entropy Neurodynamics's 3-Year ROIIC % or its related term are showing as below:
TYPTF's 3-Year ROIIC % is ranked worse than 76.57% of 1323
companies
in the Biotechnology industry
Industry Median: -4.82
vs TYPTF: -147.87
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Entropy Neurodynamics 3-Year ROIIC % Related Terms
Entropy Neurodynamics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Entropy Neurodynamics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYPTF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Entropy Neurodynamics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's 3-Year ROIIC % falls into.
Entropy Neurodynamics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -4.382 (Jun. 2025) - -9.918 (Jun. 2022) )
/
( 1.983 (Jun. 2025) - 5.649 (Jun. 2022) )
=
5.536
/
-3.666
=
-151.01%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Entropy Neurodynamics (TYPTF) has a 3-Year ROIIC % of -147.87 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Entropy Neurodynamics and its competitors. According to the industry distribution chart, Entropy Neurodynamics ranks #1013 out of 1323 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Entropy Neurodynamics' 3-Year ROIIC % too high?
Entropy Neurodynamics' current 3-Year ROIIC % is -147.87. Based on the distribution chart, Entropy Neurodynamics ranks #1013 out of 1323 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Entropy Neurodynamics' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #1013 out of 1323 companies for 3-Year ROIIC %. This places Entropy Neurodynamics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current 3-Year ROIIC % is -147.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12% above its estimated fair value. The current 3-Year ROIIC % is -147.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current 3-Year ROIIC % is -147.87 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYPTF has been successfully added to your 